Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)-Reference-Cited by-同舟云学术

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Published:2024-05 Issue:5 Volume:14 Page:1127-1144
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Simpson Eric L.^ORCID,Prajapati Vimal H.^ORCID,Leshem Yael A.^ORCID,Chovatiya Raj^ORCID,de Bruin-Weller Marjolein S.^ORCID,Ständer Sonja^ORCID,Pink Andrew E.^ORCID,Calimlim Brian M.^ORCID,Lee Wan-Ju^ORCID,Teixeira Henrique,Ladizinski Barry^ORCID,Hu Xiaofei^ORCID,Yang Yang^ORCID,Liu Yingyi^ORCID,Liu Meng^ORCID,Grada Ayman^ORCID,Platt Andrew M.^ORCID,Silverberg Jonathan I.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01157-5.pdf

Reference24 articles.

1. Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–28.e2.

2. Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–9.

3. Ronnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448–56.e30.

4. Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc. 2017;38(1):3–8.

5. Copley-Merriman C, Zelt S, Clark M, Gnanasakthy A. Impact of measuring patient-reported outcomes in dermatology drug development. Patient. 2017;10(2):203–13.